Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • HM43239 for AML
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • HM43239 for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Events

News

News

  • Press Releases
  • Presentations
  • Events

Aptose Corporate Update

Dec 6, 2020 • 2:00 pm PDT
Audio
Webcast
© 2022 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap